Foundation Fighting Blindness selects Guardion’s VectorVision CSV-1000 Diagnostic Instrument for Use in Large-Scale Multi-C...
August 06 2019 - 7:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI), announced that its standardized vision testing
instrument, the CSV-1000, has been selected by the Foundation
Fighting Blindness for inclusion in a large-scale multi-center
long-term clinical trial, the PRO-EYS Study. This study is being
conducted to evaluate vision loss and progression in patients with
degenerative retinal disease. There are expected to be about 30
sites in the study, with each site having a dedicated CSV-1000
device. The CSV-1000 is manufactured by Guardion’s VectorVision
subsidiary.
The mission of the Foundation Fighting Blindness
is to fund research that will lead to the prevention, treatment and
cure for the entire spectrum of retinal degenerative diseases. The
Foundation Fighting Blindness is the largest-non-governmental
source of research funds for inherited retinal degenerative
diseases, having raised nearly $800 million over the past 48 years
in support of its mission, and having initiated 36 clinical trials
for potential treatments linked to retinal diseases.
Dr David Evans, Guardion’s Chief Science Officer
and the founder of VectorVision, commenting on the selection of the
CSV-1000 device for this study, stated: “The Foundation Fighting
Blindness is doing important work in developing an understanding of
vision loss in patients with degenerative retinal disease. We are
pleased and honored to have our technology selected by the
Foundation Fighting Blindness for use in this clinical trial.”
About Guardion Health Sciences,
Inc.
Guardion is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with a lead
medical food product, Lumega-Z®, that addresses a depleted macular
protective pigment, a known risk factor for age-related macular
degeneration (“AMD”) and a significant component of functional
vision performance. Guardion has also developed a proprietary
medical device, the MapcatSF®, which accurately measures the
macular pigment density, thereby providing the only two-pronged
evidence-based protocol for the treatment of a depleted macular
protective pigment. Information and risk factors with respect to
Guardion and its business, including its ability to successfully
develop and commercialize its proprietary products and
technologies, may be obtained in the Company’s filings with the
Securities and Exchange Commission (“SEC”) at www.sec.gov.
About
VectorVision®
VectorVision®, operating through a wholly-owned
subsidiary of the Company, specializes in the standardization of
contrast sensitivity, glare sensitivity, low contrast acuity, and
ETDRS acuity vision testing. Its patented standardization system
provides the practitioner or researcher the ability to delineate
very small changes in visual capability, either as compared to the
population or from visit to visit. VectorVision®’s CSV-1000 device
is considered the standard of care for clinical trials.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company
Contact: |
Investor Relations
Contact: |
Michael Favish |
Matthew
Abenante |
Chief Executive
Officer |
Porter, LeVay &
Rose, Inc. |
Telephone: (858)
605-9055 x 201 |
Telephone: (212)
564-4700 |
E-mail: mfavish@guardionhealth.com |
E-mail: matthew@plrinvest.com |
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Apr 2023 to Apr 2024